VivoSense Closes $25 Million in Financing

VivoSense Inc. is $25 million richer these days.

Having closed a Series A financing round, the money will be used to accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use the funding to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.
 
VivoSense is innovating within clinical trials by developing new digital biomarkers using its proprietary VivoSense software. The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease, and other therapeutic indications. The technology allows rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.
 
“This strategic investment from the Debiopharm Innovation Fund and the Perceptive Xontogeny Venture (PXV) Fund will allow VivoSense to accelerate the development of real-world digital clinical measures from wearable and remote monitoring technologies,” CEO Dudley Tabakin said. “Measures that are trusted and valued by all stakeholders are the foundation on which all other innovations in digital health must be based. VivoSense is working to realize the potential of novel measures and technologies in regulatory and medical decision making to leverage real-world data at scale, bringing life-saving treatments to the patients who need them most.”
 
The VivoSense approach leverages the passive nature of wearable and connected technologies to assess disease symptoms, treatment side effects, and therapeutic efficacy. Specific biomarkers can be objectively assessed and transmitted to clinical professionals. This approach provides significant advantages over clinic-based assessments by removing the burden on patients and physicians and standardizing the measurement of a plethora of complicated physiological and behavioral parameters. VivoSense also conducts rigorous validation procedures to ensure these technologies are successful in a clinical setting.
 
“We are excited to support the VivoSense team as they continue to establish capabilities to collect and analyze data from wearable technologies, which we believe will supplement or replace traditional methods used in clinical trials,” said Chris Garabedian, CEO of Xontogeny and portfolio manager of the Perceptive Xontogeny Venture (PXV) Fund. “Data captured by wearable sensors will play an increasingly important role in our industry, and VivoSense is poised to become a leader in developing validated clinical biomarkers and COAs for use in registrational studies and regulatory approvals.”
 
“We are confident that this investment in VivoSense will bring substantial value to clinical research,” said Tanja Dowe, CEO of the Debiopharm Innovation Fund. “Wearable sensors and connected digital technologies have the potential to revolutionize how we study, treat and manage patients receiving novel therapies. In recent years, such tools have proliferated the consumer health market, demonstrating their utility in capturing a new type of out-of-clinic, ‘real-world’ data. Their ease of use and passive, low burden nature allows for data to be collected continuously over prolonged periods of time.”
 
The VivoSense Board of Directors will consist of current members and co-founders Tabakin and Lance Myers, as well as new additions, Garabedian and Dowe.
 
VivoSense Inc. is an agile end-to-end scientific solutions company developing digital endpoints from wearable sensor data. The company is focused on healthcare research and delivery, clinical trials, and patient wellness. VivoSense’s hypothesis-driven framework provides analytical and clinical validation leading to U.S. Food and Drug Administration approval. The proprietary VivoSense software creates and validates novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international trials.